CHDI Foundation Therapeutics Conference 2023

Apr 24 - Apr 27, 2023 | Dubrovnik, Croatia

Share this page

Close Tooltip
Copy Link Tooltip

Copy page URL

GENERATION HD2 update and further insights from the tominersen programme

Authors Peter McColgan, MD, PhD

Published date27 April, 2023

GENERATION HD2 is an ongoing Phase II study of tominersen that will evaluate the safety, biomarkers and efficacy trends of tominersen in adults with prodromal and early manifest HD. This presentation outlines the study design and current status of GENERATION HD2 and provides further insights from GENERATION HD1 and GEN-EXTEND that support the design of GENERATION HD2.

Download Current View

Welcome to Medically

The Roche Science Hub

This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.

Not a healthcare professional? Browse:

This global website is intended for healthcare professionals outside the UK, US, Canada and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

You are Leaving the Global Medically Site

By following this link, you are being redirected to another Roche page.